4-butyrolactone has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miura, D; Miura, Y; Saarinen, NM; Santti, R; Yagasaki, K | 1 |
| Ball, HW; Manson, MM; McLellan, LI; Shepherd, AG | 1 |
2 other study(ies) available for 4-butyrolactone and Experimental Hepatoma
| Article | Year |
|---|---|
Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Lignans; Liver Neoplasms, Experimental; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Rats; Tumor Cells, Cultured | 2007 |
Regulation of rat glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) subunits by chemopreventive agents and in aflatoxin B(1)-induced preneoplasia.
Topics: 4-Butyrolactone; Aflatoxin B1; Animals; Anticarcinogenic Agents; Antioxidants; Carcinogens; Catalytic Domain; Coumarins; Diet; Ellagic Acid; Enzyme Induction; Ethoxyquin; Glutamate-Cysteine Ligase; Glutathione; Inactivation, Metabolic; Liver; Liver Neoplasms, Experimental; Male; Phenobarbital; Precancerous Conditions; Rats; Rats, Inbred F344; Rats, Wistar | 2000 |